These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 10589374)

  • 1. Effects of liver disease on pharmacokinetics. An update.
    Rodighiero V
    Clin Pharmacokinet; 1999 Nov; 37(5):399-431. PubMed ID: 10589374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
    Verbeeck RK
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1147-61. PubMed ID: 18762933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic disease and drug pharmacokinetics.
    Williams RL; Mamelok RD
    Clin Pharmacokinet; 1980; 5(6):528-47. PubMed ID: 7002418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmics: elimination and dosage considerations in hepatic impairment.
    Klotz U
    Clin Pharmacokinet; 2007; 46(12):985-96. PubMed ID: 18027986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug interactions in liver disease: An update.
    Palatini P; De Martin S
    World J Gastroenterol; 2016 Jan; 22(3):1260-78. PubMed ID: 26811663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity in patients with liver disease.
    Andreasen PB
    Arch Toxicol Suppl; 1978; (1):131-6. PubMed ID: 277091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.
    Morgan DJ; McLean AJ
    Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of liver metabolic function. Clinical implications.
    Brockmöller J; Roots I
    Clin Pharmacokinet; 1994 Sep; 27(3):216-48. PubMed ID: 7988103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics in liver disease.
    Breimer DD
    Pharm Weekbl Sci; 1987 Apr; 9(2):79-84. PubMed ID: 3295764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
    Kearns GL
    Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug kinetics and alcohol ingestion.
    Sellers EM; Holloway MR
    Clin Pharmacokinet; 1978; 3(6):440-52. PubMed ID: 31257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.
    Anderson GD
    Clin Pharmacokinet; 2005; 44(10):989-1008. PubMed ID: 16176115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K
    Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic clearance measurements and pharmacokinetics.
    Keiding S; Andreasen PB
    Pharmacology; 1979; 19(3):105-10. PubMed ID: 392549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological determinants of altered pharmacokinetics in the elderly.
    Shand DG
    Gerontology; 1982; 28 Suppl 1():8-17. PubMed ID: 7044905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic drug interactions with theophylline.
    Jonkman JH; Upton RA
    Clin Pharmacokinet; 1984; 9(4):309-34. PubMed ID: 6147220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.
    Ladda MA; Goralski KB
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):67-75. PubMed ID: 26979145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of circadian rhythms on the kinetics of drugs in humans.
    Baraldo M
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):175-92. PubMed ID: 18248311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
    De Paepe P; Belpaire FM; Buylaert WA
    Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.